Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study
Abstract Background: Abemaciclib is an orally administered inhibitor of cyclin-dependent kinase (CDK) 4/6, dosed twice daily (BID) on a continuous schedule. Diarrhea is a frequently associated adverse event. It is predictable and manageable with antidiarrheal medication, typically occurs within the...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 80; no. 4_Supplement; pp. P5 - P5-14-05 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
15.02.2020
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!